XML 31 R18.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Convertible Notes Settlement Stock Issuance
In March 2019, the Company used cash of $494.1 million and an aggregate of 2.2 million shares of the Company’s common stock valued at $182.4 million for total consideration of $676.5 million to settle $493.4 million of the 2025 convertible notes. Refer to Note 15 for further discussion of this settlement transaction.
Genomic Health Combination Stock Issuance
In November 2019, the Company completed the combination with Genomic Health in a cash and stock transaction valued at $2.5 billion. Of the $2.5 billion purchase price, $1.4 billion was settled through the issuance of 17.0 million shares of common stock. The Company incurred $0.4 million in stock issuance costs as part of the transaction. Refer to Note 16 for further discussion of the consideration transferred as part of the combination with Genomic Health.
Paradigm and Viomics Acquisition Stock Issuance
In March 2020, the Company completed the acquisitions of Paradigm and Viomics. The purchase price for these acquisitions consisted of cash and stock valued at $40.4 million. Of the $40.4 million purchase price, $32.2 million is expected to be settled through the issuance of 0.4 million shares of common stock. Of the $32.2 million that will be settled through the issuance of common stock, $28.6 million was issued in March 2020, and the remainder was withheld and may become issuable as additional merger consideration on June 3, 2021 subject to the terms and conditions of the acquisition agreements.
Changes in Accumulated Other Comprehensive Income (Loss)
The amount recognized in accumulated other comprehensive income (loss) (“AOCI”) for the six months ended June 30, 2020 were as follows:
(In thousands)Foreign
Currency
Translation
Adjustments
Unrealized
Gain (Loss)
on Marketable
Securities
Accumulated
Other
Comprehensive
Income (Loss)
Balance at December 31, 2019$(25) $(75) $(100) 
Other comprehensive income (loss) before reclassifications—  1,564  1,564  
Amounts reclassified from accumulated other comprehensive loss25  —  25  
Net current period change in accumulated other comprehensive loss25  1,564  1,589  
Balance at June 30, 2020$—  $1,489  $1,489  
The amounts recognized in AOCI for the six months ended June 30, 2019 were as follows:
(In thousands)Foreign
Currency
Translation
Adjustments
Unrealized
Gain (Loss)
on Marketable
Securities
Accumulated
Other
Comprehensive
Income (Loss)
Balance at December 31, 2018$(25) $(1,397) $(1,422) 
Other comprehensive loss before reclassifications—  3,784  3,784  
Amounts reclassified from accumulated other comprehensive loss—  344  344  
Net current period change in accumulated other comprehensive loss, before tax—  4,128  4,128  
Income tax expense related to items of other comprehensive income—  (984) (984) 
Balance at June 30, 2019$(25) $1,747  $1,722  
Amounts reclassified from AOCI for the six months ended June 30, 2020 and 2019 were as follows:
Affected Line Item in the
Statements of Operations
Six Months Ended June 30,
Details about AOCI Components (In thousands)20202019
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investmentsInvestment income, net$—  $344  
Foreign currency adjustmentGeneral and administrative25  —  
Total reclassifications$25  $344